• Home
  • About GPCRCentral

GPCR News

Entries RSS | Comments RSS
  • Tags

    5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
  •  

    June 2008
    M T W T F S S
    « May   Jul »
     1
    2345678
    9101112131415
    16171819202122
    23242526272829
    30  

Dopamine lead to Impulse-control disorders

Posted on June 26, 2008 by crimsoncanary

Data presented at the Movement Disorder Society meeting show that treatment with dopamine agonists leads to compulsive behavior such as gambling, binge eating, impulsive buying and erratic sexual behavior

Filed under: gpcr | Tagged: adverse effect, agonist, Dopamine

« EMEA recommends prescribing changes for ergot derived dopamine agonists FDA recommends approval of Tolvaptan for Hyponatremia »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • June 2008
      M T W T F S S
      « May   Jul »
       1
      2345678
      9101112131415
      16171819202122
      23242526272829
      30  
  • Blogroll

    • CrimsonCanary.com
    • GPCRCentral.com
    • IonChannelCentral.com
    • Kinasecentral.com
    • Pharma Company Pipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer